EP Patent

EP2300479B1 — Nalmefene hydrochloride dihydrate

Assigned to H Lundbeck AS · Expires 2012-02-22 · 14y expired

What this patent protects

The present invention relates to the Nalmefene hydrochloride dihydrate, methods of manufacturing Nalmefene hydrochloride dihydrate, a pharmaceutical composition comprising Nalmefene hydrochloride dihydrate and a method of treatment comprising administering Nalmefene hydrochloride…

USPTO Abstract

The present invention relates to the Nalmefene hydrochloride dihydrate, methods of manufacturing Nalmefene hydrochloride dihydrate, a pharmaceutical composition comprising Nalmefene hydrochloride dihydrate and a method of treatment comprising administering Nalmefene hydrochloride dihydrate.

Drugs covered by this patent

Patent Metadata

Patent number
EP2300479B1
Jurisdiction
EP
Classification
—
Expires
2012-02-22
Drug substance claim
No
Drug product claim
No
Assignee
H Lundbeck AS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.